The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got ...

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

So when, in 2012, Jennifer Doudna and Emmanuelle Charpentier discovered CRISPR ... the best stocks to ride the incoming wave of commercialization of CRISPR-based therapies. CRISPR Therapeutics was ...

If you’re on the fence about investing in Alvotech or CRISPR Therapeutics AG because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defence system. The development of the technique earned biochemists Emmanuelle Charpentier (one of the founders of ERS ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and ...

ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

CRISPR Therapeutics (NASDAQ:CRSP) said on Wednesday that its Chief Operating Officer, Julianne Bruno, will be stepping down to pursue external opportunities, effective as of April 11, 2025.